Daiichi Sankyo was born out of the merger of Sankyo Co., Ltd., and Daiichi Pharmaceutical Co., Ltd., two drug discovery-oriented companies with histories spanning roughly a century. From the 1980s onward, both companies proceeded to expand their operations globally while developing and launching new products. Pravastatin, levofloxacin and olmesartan became blockbuster drugs* on the global market.

Daiichi Sankyo was born out of the merger of Sankyo Co., Ltd., and Daiichi Pharmaceutical Co., Ltd., two drug discovery-oriented companies, born out of research on antibiotics and anti-inflammatory agents. From the 1980s onward, both companies proceeded to expand their operations globally while developing and launching new products. Pravastatin, levofloxacin and olmesartan became blockbuster drugs on the global market.

Meanwhile, these companies maintained a strong presence for a long time in the Japanese market through their honest and trustworthy sales activities. The two companies’ histories of placing focus on science, expanding global business from early phases and progressing as Japan’s leading companies have led to creating the current Daiichi Sankyo.

### History of Sankyo

**1899**
- Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara (pictured to the left), Shokai's first president, and Shotaro Nishimura, (pictured to the left), founder of the company.

**1902**
- Launched adrenalin (Product name: Adrenalin), the world's first adrenal cortex hormone agent.

**1910**
- Dr. Umetaro Suzuki, who became Sankyo's scientific adviser, made the world's first discovery of vitamin B1 (thiamine) in rice bran and established a foundation for the theory of vitamins.

**1913**
- Changed company name from Sankyo Shoten to Sankyo Co., Ltd., and appointed Dr. Jokichi Takamine as its first president.

**1915**
- Founded as Arsenin Shokai by Dr. Jokichi Takamine (sitting), a common disease in Japan at that time.

**1921**
- Launched adrenalin (Product name: Adrenalin), the world's first adrenal cortex hormone agent.

**1951**
- Launched Luda cold medicine.

**1965**
- Launched tranexamic acid (Product name: Tranexam), an antiplasmin medicine.

**1981**
- Launched Nolpopil (Product name: Panadrel), an antihyperlipidemic agent.

**1986**
- Launched levofloxacin (Product name: Osef), an anti-inflammatory agent.

**1989**
- Launched pravastatin (Product name: Lotestrin), a globally groundbreaking antihyperlipidemic agent.

**1993**
- Launched befatopaxac (Product name: Osef), a broad-spectrum oral antibacterial agent.

**1995**
- Launched global product olmesartan (Product name: Benicar), an antihypertensive agent (Japanese launch took place in 2004).

**2002**
- Start of new Daiichi Sankyo Group

### History of Daiichi Pharmaceutical

**1913**
- Changed company name from Sankyo Shoten to Sankyo Co., Ltd., and appointed Dr. Jokichi Takamine as its first president.

**1915**
- Founded as Arsenin Shokai by Dr. Jokichi Takamine (sitting), a common disease in Japan at that time.

**1951**
- Launched Luda cold medicine.

**1965**
- Launched tranexamic acid (Product name: Tranexam), an antiplasmin medicine.

**1981**
- Launched Nolpopil (Product name: Panadrel), an antihyperlipidemic agent.

**1985**
- Launched ofloxacin (Product name: Tanid), a broad-spectrum oral antibacterial agent.
Carrying on the century-long strength in science & technology forged by its predecessors, Daiichi Sankyo continues its quest to create innovative pharmaceuticals. We have been successful in growing olmesartan and edoxaban, the fruits of our predecessors’ efforts and expertise in science & technology, into major global products. The ADC* franchise that will be key to the future of Daiichi Sankyo is also built upon these strengths, using the biotechnologies fruits of our predecessors’ efforts and expertise in science & technology, into major global products. The ADC* linker and payload (drug) portions.

**2 Index compiled by S&P Dow Jones Indices LLC and RobecoSAM AG recognizing companies that exhibit sustainability**

We are finally ready to file an NDA in fiscal 2019 for DS-8201, the first entry in our ADC franchise. We have also entered into an agreement with AstraZeneca for collaborating in global development and commercialization. This collaboration will accelerate and expand development as well as help achieve early market penetration, allowing us to deliver DS-8201 to more patients even quicker. Furthermore, as well as accelerating the process of building a structure for our oncology business in the global market, we will also allocate resources to other projects and accelerate the pace of their development.

---

**Value Creation Story**

**History of Daiichi Sankyo — Road After the Merger**

---

**Overview of initiatives under mid-term business plans**

<table>
<thead>
<tr>
<th>1st Mid-Term Business Plan</th>
<th>2nd Mid-Term Business Plan</th>
<th>3rd Mid-Term Business Plan</th>
<th>4th Mid-Term 5-Year Business Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Maximization of synergies and expansion of growth foundation</strong></td>
<td><strong>Advancement of the global hybrid business model</strong></td>
<td><strong>Promotion of measures toward sustainable growth beyond the patent cliff</strong></td>
<td><strong>Transformation toward the 2025 Vision</strong></td>
</tr>
<tr>
<td>Focus on thrombosis, cancer, and diabetes fields</td>
<td>Focus on thrombosis, cardiovascular-metabolics, and cancer fields</td>
<td>Focus on thrombosis, cardiovascular-metabolics, and cancer fields</td>
<td>Grow beyond FY2017 patent cliff</td>
</tr>
<tr>
<td>Introduced Ranbaxy into the Group in 2008</td>
<td>Expand operating foundations in Japan</td>
<td>Conduct frontline and backyard collaboration with Ranbaxy</td>
<td>Establish a foundation of sustainable growth</td>
</tr>
</tbody>
</table>

**Launches of new products**

<table>
<thead>
<tr>
<th>Japan</th>
<th>US</th>
<th>Europe</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovenor Tape</td>
<td>APOZOR</td>
<td>Effient</td>
<td>S</td>
</tr>
<tr>
<td>Atenolol</td>
<td>Daflon</td>
<td>Steviol</td>
<td>G</td>
</tr>
<tr>
<td>Lovenor Gel</td>
<td>Revasart</td>
<td>Tenero</td>
<td>S</td>
</tr>
<tr>
<td>Memory</td>
<td>Tavlan</td>
<td>Tenexus</td>
<td>S</td>
</tr>
<tr>
<td>LUKANA</td>
<td>MARKMA</td>
<td>TRAXSOR</td>
<td>S</td>
</tr>
<tr>
<td>Steviol HCT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**In-licensed products**

<table>
<thead>
<tr>
<th>Japan</th>
<th>US</th>
<th>Europe</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denosumab</td>
<td>Tivarot (Development discontinued)</td>
<td>Tivarot (Development discontinued)</td>
<td></td>
</tr>
<tr>
<td>NEKUM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Acquisition**

<table>
<thead>
<tr>
<th>Japan</th>
<th>US</th>
<th>Europe</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESI Pharma GmbH</td>
<td>UbePharma-Force, Inc</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pantrybow Laboratories Ltd.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Important management decisions**

**Restructuring/Investments**

<table>
<thead>
<tr>
<th>Japan</th>
<th>US</th>
<th>Europe</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sale of Shizuoka Plant</td>
<td>US</td>
<td>China</td>
<td></td>
</tr>
</tbody>
</table>

**ESG—Environmental—Social—Governance**

- Set the term of Board Members as one year, four out of ten Board Members are Outside Members.
- Established Nomination Committee and Compensation Committee.
- Established Audit & Supervisory Board (two out of four Members are Outside Members).
- Established Corporate Officer System.
- First time for inclusion in FTSE4Good4®; inclusion continues thereafter.
- Revision of DAICHI SANKYO Group Corporate Conduct Charter.
- Participation in United Nations Global Compact.
- Started “Daiichi Sankyo Presents Family Ties” Theater program.
- Establishment of Daiichi Sankyo Kurusu Museum.
- Launch of mobile healthcare field clinic services in developing countries.

**Selected as the winner of the Corporate Governance of the Year” for 2017**.

**2025 Vision**

- Global Pharma Innovator in Oncology.